Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

Uri Goldbourt, Solomon Behar, Henrietta Reicher-Reiss, Jacob Agmon, Elieser Kaplinsky, Eran Graft, Yehezkiel Kishon, Avraham Caspi, Joshua Weisbort, Lori Mandelzweig, Edward Abinader, Leon Aharon, Shimeon Braun, Daniel David, Michael Flich, Yaacov Friedman, Natalio Kristal, Noa Leil, Walter Markiewicz, Alon MarmorAbraham Palant, Benjamin Pelled, Babeth Rabinowitz, Leornardo Reisin, Nathan Roguin, Tiberio Rosenfeld, Zwi Schlesinger, Samuel Sclarovsky, Libi Sherf, Daniel Tzivoni, Izhar Zahavi, Monty Zion, Daniel Brunner

Research output: Contribution to journalArticlepeer-review

150 Scopus citations

Abstract

Controlled clinical trials have demonstrated the efficacy of reducing the Mood levels of tow-density lipoprotein cholesterol in reducing the incidence of coronary artery disease in hypercholesterolemic middle-aged men. However, a similar reversibility of the risk of coronary artery disease has not been demonstrated for high-density lipoprotein cholesterol elevation and triglyceride reduction. Therefore, the effect of administering 400 mg of bezafibrate retard daily versus placebo (double Mind) to patients with myocardial infarction preceding randomization by 6 months to 5 years, or a clinically manifest anginal syndrome documented by objective evidence of dynamic myocardial ischemia, or both, is being investigated. Three thousand subjects (aged 45 to 74 years) are being enrolled from 19 cardiac departments in Israel, with total serum cholesterol between 180 and 250 mg/dl, high-density lipoprotein cholesterol ≤45 mg/dl and triglycerides ≤300 mg/dl. In addition, tow-density lipoprotein cholesterol concentrations are required to be ≤180 mg/dl (≤160 mg/dl for patients aged <50 years). Patients needing lipid-modifying therapy, exhibiting ≥1 prespecified exclusion criterion or not giving informed consent, or a combination, are not randomized. The primary end points for evaluating efficacy are the incidence of fatal and nonfatal myocardial infarction, and sudden death. The hypothesized effect of bezafibrate administration under the aforementioned protocol is to reduce an estimated cumulative end point event incidence of ≥15% by 20 to 25% over an average follow-up period of 6.25 years, through early 1998, when the last patient recruited will have completed 5 years. The sample size was determined on the basis of previous studies of the natural history of myocardial infarction in Israel, a plan for 2 interim analyses, an experiment-wise, 2-sided significance level of 0.05, and a power of 0.8 to detect an effect on end point incidence. Patient safety, and protocol and medication adherence are being monitored throughout.

Original languageEnglish
Pages (from-to)909-915
Number of pages7
JournalAmerican Journal of Cardiology
Volume71
Issue number11
DOIs
StatePublished - 15 Apr 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)'. Together they form a unique fingerprint.

Cite this